All AKR-001 dose groups met the primary endpoint, with statistically significant absolute reductions in liver fat of 12-14%
All AKR-001 dose groups met the secondary endpoint of relative reduction in liver fat, with the 50mg and 70mg dose groups achieving >70% relative reductions
Blinded tolerability profile appears consistent with results from previous clinical trials evaluating AKR-001 in patients with Type 2 diabetes
SAN FRANCISCO, March 31, 2020 /PRNewswire/ — Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that all three AKR-001 dose groups in the BALANCED study met the primary endpoint of absolute change from baseline in liver fat as measured by magnetic resonance imaging – proton density fat fraction (MRI-PDFF) – at week 12. Results for the primary endpoint as well as other week 12 efficacy endpoints are summarized in the table below.
